What is Profusa?
Profusa, Inc. operates at the intersection of biotechnology and advanced engineering, specializing in the creation of tissue-integrating biosensors designed for continuous, real-time monitoring of body chemistries. The company's flagship innovation, the Lumee Oxygen Platform, has achieved significant regulatory milestones, including a CE Mark for the European market, enabling healthcare providers to monitor tissue oxygen levels with unprecedented precision. By focusing on the development of long-term, implantable sensors, Profusa addresses the limitations of traditional, intermittent diagnostic methods. The firm serves a diverse ecosystem of healthcare providers and research institutions, aiming to transform clinical management through data-driven insights and improved patient outcomes in both acute and chronic care settings.
How much funding has Profusa raised?
Profusa has raised a total of $184.7M across 9 funding rounds:
Debt
$1.2M
Private Equity
$2.8M
Series A
$2.8M
Private Equity
$11.3M
Series B
$13.2M
Grant
$7.5M
Series C
$45M
Debt
$1M
Stock/Share Issuance
$100M
Debt (2011): $1.2M, investors not publicly disclosed
Private Equity (2013): $2.8M, investors not publicly disclosed
Series A (2013): $2.8M, investors not publicly disclosed
Private Equity (2015): $11.3M, investors not publicly disclosed
Series B (2015): $13.2M backed by Qihoo 360 and Asset Management Ventures
Grant (2016): $7.5M with participation from Defense Advanced Research Projects Agency
Series C (2018): $45M led by Maxim Integrated Ventures, 3E Bioventures Capital, Atinum Investment, Tasly Holding Group, and VMS Asset Management
Debt (2020): $1M supported by PPP
Stock/Share Issuance (2025): $100M featuring Ascent Partners
Key Investors in Profusa
3E Bioventures Capital
A science-driven venture capital firm that partners with research institutions and entrepreneurs to advance medical products with significant unmet needs, leveraging expertise across the Pacific.
Maxim Integrated Ventures
The corporate venture arm of a leading semiconductor manufacturer, focusing on innovative analog and mixed-signal engineering solutions that provide strategic value to the electronics and healthcare industries.
VMS Asset Management
A Hong Kong-based private equity firm providing venture capital and corporate advisory services to support the growth of high-potential technology and healthcare enterprises.
What's next for Profusa?
With the successful completion of this major strategic investment, Profusa is poised to scale its operational capabilities and expand the reach of its Lumee Oxygen Platform. The company's strategic roadmap likely involves deepening its penetration into international markets while simultaneously investing in the next generation of biochemical sensing technology. As the demand for remote patient monitoring continues to rise, Profusa is well-positioned to capitalize on its technological lead, potentially exploring new therapeutic applications for its sensor suite. The influx of capital will be instrumental in navigating the complexities of global regulatory landscapes and scaling manufacturing processes to meet the anticipated surge in clinical adoption.
See full Profusa company page
